IL-2 mimetic (University of Washington/ neoleukin Therapeutics)

N/A

Report date: 2025/06/20 20:01:04

Base Information

Drug NameIL-2 mimetic (University of Washington/ neoleukin Therapeutics)
Drug Alias NameNeo-2/15NL-201 (Neoleukin)
ClassificationBiologics > Protein drugs > Recombinant protein
Mechanisms of ActionT lymphocytes stimulantsInterleukin-15 receptors agonistsImmunostimulants +[4] 
TargetsInterleukin-15 receptorsInterleukin-2 receptor
Therapy Area/IndicationsSolid tumoursHematologic NeoplasmsBreast Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesAustralia and New Zealand
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Washington
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNeoleukin Therapeutics IncUniversity Of Washington
Active IndicationsN/A
Inactive IndicationsSolid tumoursHematologic NeoplasmsBreast Neoplasms +[6] 

Other Information

ATC CodeN/A
Related LinksN/A